Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation.

Lashford, L. S.; Lewis, Ian; Fielding, S.; Flower, M. A.; Meller, S; Kemshead, J T; Ackery, D. M.

doi:10.1200/jco.1992.10.12.1889

Cited by 143 publications

(72 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Initial phase I-II studies with 131 I-MIBG therapy, dating back to the late 1980s, showed good tolerance and demonstrated objective tumour responses in 20-60% of patients failing to respond to modern therapies (Italian MIBG Workshop, 1987;Schwabe et al, 1987;Klingebiel et al, 1989;Lashford et al, 1992). In addition, significant pain relief was noticed even in patients who did not exhibit objective responses (Klingebiel et al, 1989).…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, given at higher doses 131 I-MIBG has proven to be active against these tumours, especially neuroblastoma (Schwabe et al, 1987;Klingebiel et al, 1989). Most clinical studies have been carried out on patients in advanced stages of the neoplasia (Italian MIBG Workshop, 1987;Klingebiel et al, 1989;Lashford et al, 1992), although recently 131 I-MIBG has been administered to poorrisk patients as up-front therapy in an attempt to improve their outcome (Mastrangelo et al, 1993(Mastrangelo et al, , 1998Weber et al, 1996).…”

mentioning

confidence: 99%

See 1 more Smart Citation

131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients

et al. 1999

View full text Add to dashboard Cite

Incomplete response to therapy may compromise the outcome of children with advanced neuroblastoma. In an attempt to improve tumour response we incorporated 131 I-metaiodobenzylguanidine ( 131 I-MIBG) in the treatment regimens of selected stage 3 and stage 4 patients. Between 1986 and 1997, 43 neuroblastoma patients older than 1 year at diagnosis, 13 with stage 3 (group A) and 30 with stage 4 disease (group B) who had completed the first-line protocol without achieving complete response entered in this study. 131 I-MIBG dose/course ranged from 2.5 to 5.5 Gbq (median, 3.7). The number of courses ranged from 1 to 5 (median 3) depending on the tumour response and toxicity. The most common acute side-effect was thrombocytopenia. Later side-effects included severe interstitial pneumonia in one patient, acute myeloid leukaemia in two, reduced thyroid reserve in 21. Complete response was documented in one stage 4 patient, partial response in 12 (two stage 3, 10 stage 4), mixed or no response in 25 (ten stage 3, 15 stage 4) and disease progression in five (one stage 3, four stage 4) Twenty-four patients (12/13 stage 3, 12/30 stage 4) are alive at 22–153 months (median, 59) from diagnosis. 131 I-MIBG therapy may increase the cure rate of stage 3 and improve the response of stage 4 neuroblastoma patients with residual disease after first-line therapy. A larger number of patients should be treated to confirm these results but logistic problems hamper prospective and coordinated studies. Long-term toxicity can be severe. © 1999 Cancer Research Campaign

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients

et al. 1999

View full text Add to dashboard Cite

show abstract

“…3 Radioiodinated MIBG can be used for imaging 4,5 as well as targeted radiotherapy. 6,7 Early studies of patients with recurrent or refractory neuroblastoma treated with 131 I MIBG have been encouraging, 8 but it appears unlikely that 131 I MIBG used alone will be curative. MIBG is a small molecule which penetrates multicellular tumor spheroids and probably tumors more readily than antibodies.…”

Section: Introductionmentioning

confidence: 99%

Noradrenaline transporter gene transfer for radiation cell kill by 131I meta-iodobenzylguanidine

Boyd¹,

Cunningham²,

Brown

et al. 1999

Gene Ther

View full text Add to dashboard Cite

Meta-iodobenzylguanidine conjugated to 131 I-iodine is an methods: (1) survival of clonogens derived from monolayer effective agent for the targeted radiotherapy of tumors of culture; (2) survival of clonogens derived from disaggreneural crest origin which express the noradrenaline transgated multicellular spheroids; and (3) spheroid growth porter (NAT). The therapeutic application of 131 I MIBG is delay. 131 I MIBG was twice as toxic to cells in spheroids presently limited to the treatment of phaeochromocytoma, compared with those in monolayers, consistent with a neuroblastoma, carcinoid and medullary thyroid carcigreater effect of radiation cross-fire (radiological bystander noma. To determine the feasibility of MIBG targeting for a effect) from 131 I ␤-radiation in the three-dimensional tumor wider range of tumor types, we employed plasmidspheroids. The highest concentration of 131 I MIBG tested mediated transfer of the NAT gene into a human glioblas-(1 MBq/ml) was nontoxic to UVW control cells or spheroids toma cell line (UVW) which does not express the NAT transfected with the NAT gene in reverse orientation. gene. This resulted in a 15-fold increase in uptake of MIBG These findings are encouraging for the development of by the host cells. A dose-dependent toxicity of 131 I MIBG NAT gene transfer-mediated 131 I MIBG therapy. to the transfectants was demonstrated using three

show abstract

“…Approximately 90% of neuroblastoma tumors are MIBG-avid, and infusions of 131 I-MIBG allow for the targeted delivery of radiation therapy directly to any sites of active disease. Initial studies showed overall response rates of 21-47% in patients with neuroblastoma [114][115][116], and subsequent studies have used ASCR after MIBG treatment, allowing for the administration of higher radiation doses. In a large phase II study, 164 patients with relapsed or refractory neuroblastoma were treated with 131 I-MIBG.…”

Section: Treatment -Relapsed and Refractory Neuroblastomamentioning

confidence: 99%

Overview and recent advances in the treatment of neuroblastoma

Whittle

Smith

Doherty

et al. 2017

Expert Review of Anticancer Therapy

325

258

View full text Add to dashboard Cite

Introduction: Children with neuroblastoma have widely divergent outcomes, ranging from cure in >90% of patients with low risk disease to <50% for those with high risk disease. Recent research has shed light on the biology of neuroblastoma, allowing for more accurate risk stratification and treatment reduction in many cases, although newer treatment strategies for children with high-risk and relapsed neuroblastoma are needed to improve outcomes. Areas covered: Neuroblastoma epidemiology, diagnosis, risk stratification, and recent advances in treatment of both newly diagnosed and relapsed neuroblastoma. Expert commentary: The identification of newer tumor targets and of novel cell-mediated immunotherapy agents may lead to novel therapeutic approaches, and clinical trials for regimens designed to target individual genetic aberrations in tumors are underway. A combination of therapeutic modalities will likely be required to improve survival and cure rates for patients with high-risk neuroblastoma.ARTICLE HISTORY

show abstract

Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation.

Cited by 143 publications

References 15 publications

131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients

131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients

Noradrenaline transporter gene transfer for radiation cell kill by 131I meta-iodobenzylguanidine

Overview and recent advances in the treatment of neuroblastoma

Contact Info

Product

Resources

About